Skip to main content
CDC Website

Colleges/Universities

Addressing the Impact of Syndemics on the Health of People with HIV and Diseases and Conditions within the Missions of NIDDK and NHLBI (R01 Clinical Trial Optional)

This Notice of Funding Opportunity (NOFO) invites research projects that seek solutions to the development, exacerbation, and ineffective management of co-occurring conditions in marginalized communities of People with HIV (PWH). Projects must be based on a syndemics (synergistic epidemic) framework with a focus on the impact of racism, marginalization, discrimination, and/or stigma and their inter-relationships with social and structural risks.

Advancing Technologies to Improve Delivery of Pharmacological, Gene Editing, and other Cargoes for HIV and SUD Mechanistic or Therapeutic Research (R01 Clinical Trial Optional)

The purpose of this notice of funding opportunity (NOFO) is to develop technologies to improve the delivery of pharmacological, gene editing, or other cargoes for HIV and substance use disorder (SUD) mechanistic or therapeutic research.

Effect of HIV and Substance Use Comorbidity on the Placenta and Maternal Outcomes (R01 Clinical Trial Optional)

Human immunodeficiency virus (HIV) infection is widely prevalent in individuals in the reproductive age group. Globally, an estimated 1.3 million people living with HIV (PWH) become pregnant each year (UNAIDS data, 2019). With the advent of antiretroviral therapy (ART), significant progress has been made in the prevention of vertical transmission of HIV. However, although ART has clear benefits in preventing vertical transmission, ART regimens are associated with higher rates of preterm birth, stillbirth, and early infant death.

Long-Acting Drug Delivery Systems for ART Optimization in Children Living with HIV-1 II (LADDS II) (R61/R33 Clinical Trial Not Allowed)

The purpose of this Notice of Funding Opportunity (NOFO) is to accelerate the development of safe and effective long-acting drug delivery systems for improved, simplified treatment of HIV-1 in children. This NOFO invites applicants engaged in the development of existing long-acting platforms at early stages of development stages to perform specific preclinical activities that enable product optimization and accelerated translation to HIV-infected children. Collaborative research partnerships with industry are required.

Comprehensive Alcohol-HIV/AIDS Research Center (P60 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) seeks applications for research center grants to conduct high-impact research on alcohol and HIV/AIDS. Through this NOFOA, NIAAA seeks to encourage research applications aimed to address the impact of alcohol use (and related other substance use, mental health, and pharmacological/medication complications) on the most important challenges for controlling and ending HIV/AIDS pandemic.

Multidisciplinary Research to Accelerate Hepatitis B Cure in Persons Living with HIV and HBV (U19 Clinical Trial Not Allowed)

The purpose of this Notice of Funding Opportunity (NOFO) is to support research to better understand the impact of host and viral heterogeneity on pathogenesis of disease, viral persistence and immunopathology of Hepatitis B (HBV) and inform cure strategies for HBV in people living with HIV (PLWH). Applicants will establish multidisciplinary teams that span the clinical and basic/translational research arenas and establish an observational cohort to accelerate discovery and increase clinical impact.

HIV Vaccine Research and Design (HIVRAD) Program (P01 Clinical Trial Not Allowed)

The purpose of this Notice of Funding Opportunity (NOFO) is to support multi-component, multi-disciplinary projects that address scientific questions relevant to AIDS prophylactic vaccine discovery research. Extensive evaluation of vaccine concepts in non-human primate models may be included.